Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongguan Yixin Prescription is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Hangzhou Hospital of Traditional Chinese Medicine. It is primarily investigated for the treatment of coronary heart disease (CHD), specifically targeting coronary artery stenosis and the prevention of restenosis following percutaneous coronary intervention (PCI). The prescription is designed based on TCM principles to "tonify Qi and invigorate blood," addressing the underlying pathologies of Qi deficiency and blood stasis that contribute to atherosclerosis. Clinical studies, such as ChiCTR2400087201, evaluate its efficacy in improving cardiac function, reducing the incidence of major adverse cardiovascular events (MACE), and lowering inflammatory markers in patients post-PCI.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongguan Yixin Prescription.